Tag: immuno-oncology

Biothera Pharmaceuticals Enters Cancer Immunotherapy Clinical Trial Collaboration Agreement

Phase 1b/2 clinical study in colorectal cancer to evaluate Imprime PGG in combination with PD-L1 immunotherapy and anti-VEGF therapy EAGAN, MN — November 28, 2017 — Biothera Pharmaceuticals, Inc. today announced that it has entered into a clinical trial collaboration agreement with Genentech, Inc., a member of the Roche Group, to assess the safety and efficacy of Biothera’s Imprime PGG in combination with Genentech’s atezolizumab...

Read More

Biothera Pharmaceuticals to Present its Phase 2 Cancer Immunotherapy Data at International Molecular Medicine Tri-Conference

EAGAN, MN — March 10, 2016 — Biothera Pharmaceuticals Inc. today will present data on its Phase 2 cancer immunotherapy Imprime PGG, the Company’s first-in-class, systemically administered beta glucan PAMP (Pathogen Associated Molecular Patterning molecule) at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference 2016, taking place at the Moscone Convention Center, San Francisco. Jeremy Graff, Ph.D., Chief Scientific Officer and Senior Vice President, Research at Biothera...

Read More

Biothera Announces Publication of Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies

Results published in Investigational New Drugs: The Journal of New Anticancer Agents Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm and randomized Phase 2 studies With significant milestones anticipated throughout 2016, Biothera is advancing Imprime PGG towards registration trials by 2018 EAGAN, MN — February 25, 2016 — Biothera Pharmaceuticals Inc. today announced the peer-reviewed...

Read More